Nektar Therapeutics (0UNL.L)
USD 1.01
(-1.02%)
USD 1.01
(-1.02%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 90.12 Million USD | -2.1% |
| 2022 | 92.05 Million USD | -9.67% |
| 2021 | 101.9 Million USD | -33.36% |
| 2020 | 152.91 Million USD | 33.41% |
| 2019 | 114.61 Million USD | -90.4% |
| 2018 | 1.19 Billion USD | 287.81% |
| 2017 | 307.71 Million USD | 86.0% |
| 2016 | 165.43 Million USD | -28.32% |
| 2015 | 230.78 Million USD | 14.99% |
| 2014 | 200.7 Million USD | 34.77% |
| 2013 | 148.92 Million USD | 83.42% |
| 2012 | 81.19 Million USD | 13.59% |
| 2011 | 71.48 Million USD | -55.06% |
| 2010 | 159.03 Million USD | 121.1% |
| 2009 | 71.93 Million USD | -20.24% |
| 2008 | 90.18 Million USD | -66.97% |
| 2007 | 273.02 Million USD | 25.4% |
| 2006 | 217.71 Million USD | 72.41% |
| 2005 | 126.27 Million USD | 10.51% |
| 2004 | 114.27 Million USD | 7.54% |
| 2003 | 106.25 Million USD | 12.03% |
| 2002 | 94.84 Million USD | 22.43% |
| 2001 | 77.46 Million USD | 50.05% |
| 2000 | 51.62 Million USD | 24.83% |
| 1999 | 41.35 Million USD | 89.76% |
| 1998 | 21.79 Million USD | 34.13% |
| 1997 | 16.24 Million USD | 135.49% |
| 1996 | 6.9 Million USD | 102.94% |
| 1995 | 3.4 Million USD | 100.0% |
| 1994 | 1.7 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 23.48 Million USD | 8.55% |
| 2024 Q1 | 21.63 Million USD | -9.4% |
| 2023 FY | 90.12 Million USD | -2.1% |
| 2023 Q1 | 21.59 Million USD | -1.95% |
| 2023 Q2 | 20.49 Million USD | -5.07% |
| 2023 Q3 | 24.14 Million USD | 17.78% |
| 2023 Q4 | 23.88 Million USD | -1.07% |
| 2022 Q2 | 21.58 Million USD | -13.04% |
| 2022 Q1 | 24.82 Million USD | -0.75% |
| 2022 FY | 92.05 Million USD | -9.67% |
| 2022 Q4 | 22.02 Million USD | -6.78% |
| 2022 Q3 | 23.62 Million USD | 9.45% |
| 2021 Q1 | 23.64 Million USD | 0.79% |
| 2021 Q2 | 28.33 Million USD | 19.8% |
| 2021 FY | 101.9 Million USD | -33.36% |
| 2021 Q3 | 24.92 Million USD | -12.03% |
| 2021 Q4 | 25 Million USD | 0.35% |
| 2020 Q3 | 30.03 Million USD | -38.52% |
| 2020 Q2 | 48.84 Million USD | -3.41% |
| 2020 FY | 152.91 Million USD | 33.41% |
| 2020 Q4 | 23.46 Million USD | -21.88% |
| 2020 Q1 | 50.57 Million USD | 49.35% |
| 2019 Q3 | 29.21 Million USD | 25.32% |
| 2019 Q1 | 28.22 Million USD | -29.14% |
| 2019 FY | 114.61 Million USD | -90.4% |
| 2019 Q4 | 33.86 Million USD | 15.89% |
| 2019 Q2 | 23.31 Million USD | -17.39% |
| 2018 Q4 | 39.82 Million USD | 43.46% |
| 2018 Q3 | 27.76 Million USD | -97.45% |
| 2018 FY | 1.19 Billion USD | 287.81% |
| 2018 Q2 | 1.08 Billion USD | 2761.06% |
| 2018 Q1 | 38.01 Million USD | -60.18% |
| 2017 Q3 | 152.92 Million USD | 342.13% |
| 2017 Q1 | 24.72 Million USD | -33.97% |
| 2017 Q2 | 34.58 Million USD | 39.88% |
| 2017 Q4 | 95.46 Million USD | -37.57% |
| 2017 FY | 307.71 Million USD | 86.0% |
| 2016 Q4 | 37.45 Million USD | 3.07% |
| 2016 FY | 165.43 Million USD | -28.32% |
| 2016 Q2 | 32.76 Million USD | -44.35% |
| 2016 Q1 | 58.88 Million USD | 49.56% |
| 2016 Q3 | 36.33 Million USD | 10.89% |
| 2015 Q3 | 59.95 Million USD | 164.56% |
| 2015 FY | 230.78 Million USD | 14.99% |
| 2015 Q2 | 22.66 Million USD | -79.17% |
| 2015 Q1 | 108.8 Million USD | 456.5% |
| 2015 Q4 | 39.37 Million USD | -34.33% |
| 2014 Q1 | 19.77 Million USD | -36.52% |
| 2014 Q2 | 28.51 Million USD | 44.22% |
| 2014 Q3 | 132.87 Million USD | 366.0% |
| 2014 Q4 | 19.55 Million USD | -85.29% |
| 2014 FY | 200.7 Million USD | 34.77% |
| 2013 Q1 | 23 Million USD | 8.79% |
| 2013 FY | 148.92 Million USD | 83.42% |
| 2013 Q4 | 31.14 Million USD | -48.86% |
| 2013 Q3 | 60.9 Million USD | 79.87% |
| 2013 Q2 | 33.86 Million USD | 47.2% |
| 2012 Q3 | 18.41 Million USD | -22.26% |
| 2012 Q4 | 21.14 Million USD | 14.85% |
| 2012 Q1 | 17.94 Million USD | 13.73% |
| 2012 Q2 | 23.68 Million USD | 31.95% |
| 2012 FY | 81.19 Million USD | 13.59% |
| 2011 Q2 | 17.33 Million USD | 53.39% |
| 2011 FY | 71.48 Million USD | -55.06% |
| 2011 Q4 | 15.78 Million USD | -41.69% |
| 2011 Q3 | 27.06 Million USD | 56.18% |
| 2011 Q1 | 11.29 Million USD | -75.07% |
| 2010 Q4 | 45.31 Million USD | 19.48% |
| 2010 Q1 | 33.23 Million USD | -14.8% |
| 2010 FY | 159.03 Million USD | 121.1% |
| 2010 Q2 | 42.56 Million USD | 28.06% |
| 2010 Q3 | 37.92 Million USD | -10.9% |
| 2009 Q1 | 9.71 Million USD | -65.75% |
| 2009 Q4 | 39 Million USD | 281.58% |
| 2009 Q3 | 10.22 Million USD | -21.29% |
| 2009 FY | 71.93 Million USD | -20.24% |
| 2009 Q2 | 12.98 Million USD | 33.75% |
| 2008 Q1 | 19.99 Million USD | -69.6% |
| 2008 FY | 90.18 Million USD | -66.97% |
| 2008 Q4 | 28.35 Million USD | 32.25% |
| 2008 Q3 | 21.43 Million USD | 5.09% |
| 2008 Q2 | 20.4 Million USD | 2.05% |
| 2007 Q1 | 85.01 Million USD | 21.62% |
| 2007 FY | 273.02 Million USD | 25.4% |
| 2007 Q4 | 65.77 Million USD | 16.78% |
| 2007 Q3 | 56.32 Million USD | -14.56% |
| 2007 Q2 | 65.91 Million USD | -22.47% |
| 2006 FY | 217.71 Million USD | 72.41% |
| 2006 Q1 | 28.95 Million USD | -11.93% |
| 2006 Q2 | 60.22 Million USD | 107.96% |
| 2006 Q4 | 69.9 Million USD | 19.22% |
| 2006 Q3 | 58.63 Million USD | -2.64% |
| 2005 FY | 126.27 Million USD | 10.51% |
| 2005 Q4 | 32.88 Million USD | -9.55% |
| 2005 Q2 | 28.55 Million USD | 0.2% |
| 2005 Q1 | 28.49 Million USD | -9.16% |
| 2005 Q3 | 36.35 Million USD | 27.33% |
| 2004 Q2 | 28.52 Million USD | 10.44% |
| 2004 Q3 | 28.54 Million USD | 0.07% |
| 2004 FY | 114.27 Million USD | 7.54% |
| 2004 Q4 | 31.36 Million USD | 9.88% |
| 2004 Q1 | 25.83 Million USD | 0.81% |
| 2003 Q3 | 27.35 Million USD | -1.41% |
| 2003 Q2 | 27.74 Million USD | 8.7% |
| 2003 FY | 106.25 Million USD | 12.03% |
| 2003 Q4 | 25.62 Million USD | -6.33% |
| 2003 Q1 | 25.52 Million USD | 12.81% |
| 2002 FY | 94.84 Million USD | 22.43% |
| 2002 Q4 | 22.63 Million USD | -2.53% |
| 2002 Q3 | 23.21 Million USD | 4.35% |
| 2002 Q2 | 22.25 Million USD | -16.81% |
| 2002 Q1 | 26.74 Million USD | 10.67% |
| 2001 Q3 | 22.4 Million USD | 33.37% |
| 2001 Q1 | 14.09 Million USD | 7.23% |
| 2001 FY | 77.46 Million USD | 50.05% |
| 2001 Q2 | 16.79 Million USD | 19.17% |
| 2001 Q4 | 24.16 Million USD | 7.86% |
| 2000 Q1 | 10.63 Million USD | -18.66% |
| 2000 FY | 51.62 Million USD | 24.83% |
| 2000 Q3 | 14.06 Million USD | 1.97% |
| 2000 Q4 | 13.14 Million USD | -6.51% |
| 2000 Q2 | 13.78 Million USD | 29.68% |
| 1999 Q4 | 13.07 Million USD | 23.01% |
| 1999 Q3 | 10.62 Million USD | 7.6% |
| 1999 FY | 41.35 Million USD | 89.76% |
| 1999 Q2 | 9.87 Million USD | 26.95% |
| 1999 Q1 | 7.78 Million USD | 22.17% |
| 1998 Q4 | 6.36 Million USD | 30.41% |
| 1998 Q3 | 4.88 Million USD | -26.89% |
| 1998 Q2 | 6.67 Million USD | 72.81% |
| 1998 FY | 21.79 Million USD | 34.13% |
| 1998 Q1 | 3.86 Million USD | -19.31% |
| 1997 Q1 | 3.17 Million USD | 44.41% |
| 1997 Q3 | 4.3 Million USD | 8.46% |
| 1997 Q4 | 4.79 Million USD | 11.16% |
| 1997 FY | 16.24 Million USD | 135.49% |
| 1997 Q2 | 3.97 Million USD | 25.06% |
| 1996 Q3 | 1.8 Million USD | 28.57% |
| 1996 Q4 | 2.2 Million USD | 22.22% |
| 1996 Q1 | 1.5 Million USD | 87.5% |
| 1996 FY | 6.9 Million USD | 102.94% |
| 1996 Q2 | 1.4 Million USD | -6.67% |
| 1995 Q1 | 600 Thousand USD | 20.0% |
| 1995 Q2 | 1 Million USD | 66.67% |
| 1995 Q4 | 800 Thousand USD | -20.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| 1995 FY | 3.4 Million USD | 100.0% |
| 1994 Q1 | 400 Thousand USD | 0.0% |
| 1994 FY | 1.7 Million USD | 0.0% |
| 1994 Q4 | 500 Thousand USD | -16.67% |
| 1994 Q2 | 300 Thousand USD | -25.0% |
| 1994 Q3 | 600 Thousand USD | 100.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -15.359% |
| Dynavax Technologies Corporation | 232.28 Million USD | 61.202% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 85.166% |
| Perrigo Company plc | 4.65 Billion USD | 98.064% |
| Illumina, Inc. | 4.5 Billion USD | 97.999% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.79% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -7479.647% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.939% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 99.399% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 29.062% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.313% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 96.952% |
| Biogen Inc. | 9.83 Billion USD | 99.084% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 48.862% |
| Evolus, Inc. | 202.08 Million USD | 55.404% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -329.807% |
| bluebird bio, Inc. | 29.49 Million USD | -205.529% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 22.532% |
| FibroGen, Inc. | 147.75 Million USD | 39.005% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 98.681% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 1455.014% |
| Geron Corporation | 237 Thousand USD | -37926.16% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 95.071% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 77.433% |
| Myriad Genetics, Inc. | 678.4 Million USD | 86.716% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -148.441% |
| Zoetis Inc. | 8.54 Billion USD | 98.945% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -2474.914% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 97.621% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 96.275% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.087% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 88.558% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -951.231% |
| Verastem, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 66.695% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -188.4% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 92.752% |
| OPKO Health, Inc. | 863.49 Million USD | 89.563% |
| Exelixis, Inc. | 1.83 Billion USD | 95.076% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 95.224% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 81.317% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -468.844% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | 63.862% |
| Insmed Incorporated | 305.2 Million USD | 70.472% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 89.132% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -235.988% |
| TG Therapeutics, Inc. | 233.66 Million USD | 61.431% |
| Incyte Corporation | 3.69 Billion USD | 97.561% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 91.411% |